Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (7): 729-734.doi: 10.3969/j.issn.1000-6621.2021.07.015

• 综述 • 上一篇    下一篇


郑璐瑶*, 陆宇(), 陈效友()   

  1. 101149 首都医科大学附属北京胸科医院 耐药结核病研究北京市重点实验室 北京市结核病胸部肿瘤研究所药物研究室(郑璐瑶、陆宇);首都医科大学附属北京地坛医院(陈效友)
  • 收稿日期:2021-04-02 出版日期:2021-07-10 发布日期:2021-07-09
  • 通信作者: 郑璐瑶,陆宇,陈效友;
  • 基金资助:

Research and development/exploitation of therapeutic drugs for NTM pulmonary disease:present situation and challenges

ZHENG Lu-yao*, LU Yu(), CHEN Xiao-you()   

  1. *Beijing Key Laboratory of Drug Resistance Tuberculosis Research,Department of Pharmacology,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China
  • Received:2021-04-02 Online:2021-07-10 Published:2021-07-09
  • Contact: ZHENG Lu-yao,LU Yu,CHEN Xiao-you;



关键词: 分枝杆菌感染, 非典型性, 抗结核药, 综述文献(主题)


Non-tuberculous mycobacteria (NTM) belongs to the genus mycobacterium,which is “close relative” to Mycobacterium tuberculosis. In recent years, the prevalence of chronic lung diseases caused by NTM is increasing at an alarming rate, even exceeding Mycobacterium tuberculosis in some countries. At present, the clinical treatment mainly relies on long-term therapy with combined medication, but the results are often unsatisfactory. Therefore, there is an urgent need for noval and more effective antimicrobials as well as new chemotherapy regimen. This article reviews the current situation and challenges in NTM drug development, in order to provide new insight for the treatment of NTM pulmonary disease.

Key words: Mycobacterium infections, atypical, Antitubercular agents, Review literature as topic